Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 415

1.

Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study.

Mozzillo N, Pasquali S, Santinami M, Testori A, Di Marzo M, Crispo A, Patuzzo R, Verrecchia F, Botti G, Montella M, Rossi CR, Caracò C.

Eur J Surg Oncol. 2015 Mar 11. pii: S0748-7983(15)00078-5. doi: 10.1016/j.ejso.2015.02.005. [Epub ahead of print]

PMID:
25800935
2.

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.

Caputo E, Miceli R, Motti ML, Taté R, Fratangelo F, Botti G, Mozzillo N, Carriero MV, Cavalcanti E, Palmieri G, Ciliberto G, Pirozzi G, Ascierto PA.

J Transl Med. 2015;13:2069. doi: 10.1186/1479-5876-13-S1-P1. No abstract available.

3.

Combined Papillary and Mucoepidermoid Carcinoma of the Thyroid Gland: a Possible Collision Tumor Diagnosed on Fine-Needle Cytology. Report of a Case with Immunocytochemical and Molecular Correlations.

Fulciniti F, Vuttariello E, Calise C, Monaco M, Pezzullo L, Chiofalo MG, Di Gennaro F, Malzone MG, Campanile AC, Losito NS, Botti G, Chiappetta G.

Endocr Pathol. 2015 Mar 14. [Epub ahead of print]

PMID:
25771987
4.

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.

Manca A, Lissia A, Capone M, Ascierto PA, Botti G, Caracò C, Stanganelli I, Colombino M, Sini M, Cossu A, Palmieri G.

J Transl Med. 2015 Jan 28;13:37. doi: 10.1186/s12967-015-0401-8.

5.

HtrA1 loss is related to aggressive behavior parameters in sentinel node positive breast cancer.

Franco R, Collina F, Di Bonito M, Botti G, Montanaro D, Di Maio L, Vincenzi B, Landi G, D'Aiuto M, Caraglia M, Baldi A.

Histol Histopathol. 2014 Dec 22. [Epub ahead of print]

PMID:
25530301
6.

Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.

Perrone F, Nuzzo F, Di Rella F, Gravina A, Iodice G, Labonia V, Landi G, Pacilio C, Rossi E, De Laurentiis M, D'Aiuto M, Botti G, Forestieri V, Lauria R, De Placido S, Tinessa V, Daniele B, Gori S, Colantuoni G, Barni S, Riccardi F, De Maio E, Montanino A, Morabito A, Daniele G, Di Maio M, Piccirillo MC, Signoriello S, Gallo C, de Matteis A.

Ann Oncol. 2015 Apr;26(4):675-682. Epub 2014 Dec 8.

PMID:
25488686
7.

Ran signaling in melanoma: implications for the development of alternative therapeutic strategies.

Caputo E, Wang E, Valentino A, Crispi S, De Giorgi V, Fico A, Ficili B, Capone M, Anniciello A, Cavalcanti E, Botti G, Mozzillo N, Ascierto PA, Marincola FM, Travali S.

Cancer Lett. 2015 Feb 1;357(1):286-96. doi: 10.1016/j.canlet.2014.11.033. Epub 2014 Nov 20.

PMID:
25444926
8.

Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).

Avallone A, Piccirillo MC, Delrio P, Pecori B, Di Gennaro E, Aloj L, Tatangelo F, D'Angelo V, Granata C, Cavalcanti E, Maurea N, Maiolino P, Bianco F, Montano M, Silvestro L, Terranova Barberio M, Roca MS, Di Maio M, Marone P, Botti G, Petrillo A, Daniele G, Lastoria S, Iaffaioli VR, Romano G, Caracò C, Muto P, Gallo C, Perrone F, Budillon A.

BMC Cancer. 2014 Nov 24;14:875. doi: 10.1186/1471-2407-14-875.

9.

KIT genetic alterations in anorectal melanomas.

Santi R, Simi L, Fucci R, Paglierani M, Pepi M, Pinzani P, Merelli B, Santucci M, Botti G, Urso C, Massi D.

J Clin Pathol. 2015 Feb;68(2):130-4. doi: 10.1136/jclinpath-2014-202572. Epub 2014 Nov 14.

PMID:
25398993
10.

Borderline Brenner tumor of the ovary: A case report with immunohistochemical and molecular study.

De Cecio R, Cantile M, Collina F, Marra L, Santonastaso C, Scaffa C, Botti G, Losito N.

J Ovarian Res. 2014 Oct 29;7(1):101. [Epub ahead of print]

11.

Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype.

Capasso I, Esposito E, de Laurentiis M, Maurea N, Cavalcanti E, Botti G, Petrillo A, Montella M, D'Aiuto M, Coppola C, Crispo A, Grimaldi M, Frasci G, Fucito A, Ciliberto G, D'Aiuto G.

Diabetol Metab Syndr. 2014 Sep 26;6(1):105. doi: 10.1186/1758-5996-6-105. eCollection 2014.

12.

Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression.

Panza E, De Cicco P, Armogida C, Scognamiglio G, Gigantino V, Botti G, Germano D, Napolitano M, Papapetropoulos A, Bucci M, Cirino G, Ianaro A.

Pigment Cell Melanoma Res. 2015 Jan;28(1):61-72. doi: 10.1111/pcmr.12312. Epub 2014 Oct 6.

PMID:
25205294
13.

Midface lift: our current approaches.

Botti G, Botti C.

Handchir Mikrochir Plast Chir. 2014 Aug;46(4):224-33. doi: 10.1055/s-0034-1385927. Epub 2014 Aug 27.

PMID:
25162240
14.

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.

Caputo E, Miceli R, Motti ML, Taté R, Fratangelo F, Botti G, Mozzillo N, Carriero MV, Cavalcanti E, Palmieri G, Ciliberto G, Pirozzi G, Ascierto PA.

J Transl Med. 2014 Jul 31;12:216. doi: 10.1186/s12967-014-0216-z.

15.

Coexistence of granular cell tumor and invasive ductal breast cancer in contralateral breasts: a case report.

Di Bonito M, Cantile M, Collina F, De Cecio R, Petrosino T, Botti G.

Int J Mol Sci. 2014 Jul 25;15(8):13166-71. doi: 10.3390/ijms150813166.

16.

Silicone lymphadenopathy: presentation of a further case containing asteroid bodies on fine-needle cytology sample.

Malzone MG, Campanile AC, Gioioso A, Fucito A, D'Aiuto G, Botti G, Fulciniti F.

Diagn Cytopathol. 2015 Jan;43(1):57-9. doi: 10.1002/dc.23123. Epub 2014 Jul 4.

PMID:
24995825
17.

SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression.

Botti G, Scognamiglio G, Marra L, Collina F, Di Bonito M, Cerrone M, Grilli B, Anniciello A, Franco R, Fulciniti F, Ascierto PA, Cantile M.

Virchows Arch. 2014 Sep;465(3):331-8. doi: 10.1007/s00428-014-1616-4. Epub 2014 Jul 4.

PMID:
24993904
18.

CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells.

Ieranò C, Santagata S, Napolitano M, Guardia F, Grimaldi A, Antignani E, Botti G, Consales C, Riccio A, Nanayakkara M, Barone MV, Caraglia M, Scala S.

Cell Death Dis. 2014 Jul 3;5:e1310. doi: 10.1038/cddis.2014.269.

19.

Tissue micro arrays for immunohistochemical detection of inflammatory infiltrates in renal cell carcinoma.

Scognamiglio G, Cantile M, Scala S, Cecere S, Russo F, Collina F, Marra L, Sabbatino F, Botti G, Franco R.

Int J Clin Exp Med. 2014 Apr 15;7(4):1175-9. eCollection 2014. No abstract available.

20.

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.

Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T, Pisconti S, Giuliani F, Barone C, Cartenì G, Rachiglio AM, Montesarchio V, Tonini G, Rizzi D, Cinieri S, Bordonaro R, Febbraro A, De Vita F, Orditura M, Fenizia F, Lambiase M, Rinaldi A, Tatangelo F, Botti G, Colucci G.

Ann Oncol. 2014 Sep;25(9):1756-61. doi: 10.1093/annonc/mdu230. Epub 2014 Jun 18.

PMID:
24942275
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk